La cadena de opciones muestra datos clave de las opciones de acciones de Alaunos Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Alaunos Therapeutics..

Alaunos Therapeutics (NASDAQ:TCRT) Bolsa, Cadena de Opciones

Alaunos Therapeutics

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics Inc

News

PXLW

Pixelworks Enters $10M "At-The-Market" Equity Offering Agreement With Roth Capital, Allowing Periodic Common Stock Sales With 2.5% Commission; Roth To Act As Sales Agent

Trading Ideas

GOOGL

LBRDA

RIVN

Soros Fund Management 13F Shows Decreased Stake In Rivian Automotive Convertible Notes By 21% To $155.9M In Principal; Decreased Stake In Wayfair Convertible Notes By 11% To $119.5M In Principal; Decreased Stake In Liberty Broadband Corp By 19% To 1,119,893 Shares; Decreased Stake In Alphabet Class A By 43% To 517,890 Shares; Decreased Put Position In Ishares IBoxx High Yield Corporate Bond ETF By 40% To 1,500,000 Shares

Discover Financial Reports $100.7B In Credit Card Loans As Of October 2024, Up From $98.7B YoY; Average Balances Remain Stable At $100.2B; Net Principal Charge-Off Rate Drops To 4.31% With Disaster Relief Impact, Though Up From 4.42% YoY; Delinquency Rate Rises Slightly To 3.87%

Management

Zillow Group Appoints Jun Choo As COO

Offerings

GYRE

Gyre Therapeutics Files For Up To $150M Mixed Shelf

WIIM

IZEA

IZEA Worldwide shares are trading lower after the company reported worse-than-expected Q3 financial results.

<p>BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.58) by 32.76 percent.</p>


Earnings

Earnings Beats

BKYI

BIO-key Intl Q3 2024 Adj EPS $(0.39) Beats $(0.58) Estimate

TFFP

TFF Pharmaceutical shares are trading lower after the company announced it will wind down its operations.

<p>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.52) by 53.85 percent.</p>


ENVB

Enveric Biosciences Q3 2024 GAAP EPS $(0.24) Beats $(0.52) Estimate

AKYA

Akoya Biosciences shares are trading lower after the company reported worse-than-expected Q3 financial results.

DOCN

OKTA

Soros Fund Management 13F Shows Increased Put Position In SPDR S&P 500 ETF By 608% To 2,123,000 Shares; Increased Stake In Ishares Financial Select Sector SPDR ETF By 22,720% To 2,800,000 Shares; Increased Stake In JD.com By 114% To 2,730,000 Shares; Increased Stake In Okta Convertible Notes By 75% To $79.1M In Principal; Increased Stake In DigitalOcean Convertible Notes By 302% To $116.5M In Principal

Buybacks

Primerica Board Authorizes $450M Share Repurchase Program To Occur Through December 31, 2025

XPON

Expion360 shares are trading lower after the company reported a year-over-year decline in Q3 revenue results.

Asset Sales

BLFS

BioLife Solutions Sells Subsidiary, Arctic Solutions, For $6.1M

BENF

Beneficient Q2 2025 Revenue $8.6M Vs $(42.8M) YoY

<p>Chardan Capital  analyst Keay Nakae   maintains Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Buy and maintains $55 price target.</p>


Price Target

Analyst Ratings

Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $55 Price Target

DBGI

DBGIW

Digital Brands Group shares are trading lower after the company reported worse-than-expected Q3 EPS results and a year-over-year decline in Q3 revenue.

<p>As the U.S. prepares for what could be a defining legislative session for digital assets, expectations are mounting around potential <a href="https://www.benzinga.com/topic/crypto-regulations">shifts in crypto regulation</a>. </p>
<p><strong>Robert Leshner</strong>, CEO and co-founder of <strong>Superstate</strong> sees this as a turning point, with Congress possibly advancing long-awaited laws to provide clarity in the industry. </p>
<p>Speaking ahead of the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets event</a>, Leshner shared his outlook on what might come next.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41984825/trump-rally-fades-as-investors-await-powells-remarks-bitcoin-drops-below-90000-whats-driving-markets-thursday">Trump Rally Fades As Investors Await Powell&#8217;s Remarks, Bitcoin Drops Below $90,000: What&#8217;s Driving Markets Thursday?</a></strong></p>
<h3 class="wp-block-heading">A New Framework for Digital Assets</h3>
<p>With the prospect of a Congress more favorable to digital assets, Leshner anticipates that lawmakers will focus on three core areas: a framework for stablecoins, structured definitions for digital assets, and repealing the SEC's SAB-121 guidance on crypto custody. </p>
<p>He pointed out the impact of these potential regulations, explaining that they could finally end a "decade of legal grays" and replace it with "black and white rules" that would allow the industry to expand within a clear legal structure.</p>
<p><figure class="wp-block-image size-full"><a href="https://benzinga.swoogo.com/digital-assets/6342807"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13235418/905735A6-57D3-4874-9AA1-75D037842DB3-1-13.gif" alt="" class="wp-image-646877" /></a></figure></p>
<h3 class="wp-block-heading">Addressing Stablecoins and Custody Rules</h3>
<p>One priority on the legislative horizon is a stablecoin bill that would establish guidelines for stablecoins in the U.S. The proposed law aims to clarify the issuance and management of stablecoins, which have become widely used in digital transactions. </p>
<p>Leshner also emphasized the potential impact of repealing the <strong>SEC's SAB-121</strong> guidance, which has restricted crypto custody by placing complex accounting requirements on crypto-related firms. Removing these restrictions, he believes, would open new possibilities for digital asset custody services in the U.S.</p>
<h3 class="wp-block-heading">Defining Crypto Assets</h3>
<p>Leshner highlighted the importance of clear definitions for digital assets, noting that confusion around terminology has long been a barrier for the industry. Proposed measures such as FIT21 aim to categorize digital assets, creating a structured approach that could aid mainstream adoption. Leshner views these definitions as essential for aligning crypto with existing financial regulations, creating a foundation for the industry to grow.</p>
<p>As Leshner prepares to speak at the <strong><a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a></strong> event, his perspective offers insight into how upcoming legislation could reshape the future of digital finance in the U.S.</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<p><em>As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field.&nbsp;<a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a>&nbsp;event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.</em></p>
<p><em>Image via Unsplash</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

Could New Legislation Finally Bring Clarity To US Crypto Rules? Industry Expert Weighs In

MCHP

Soros Fund Management 13F Shows Added Put Position In SPDR S&P 500 ETF With 2,123,000 Shares; Added Stake In Smurfit Westrock With 6,896,971 Shares; Added Put Position In Ishares Russell 2000 ETF With 800,000 Shares; Added Stake In Microchip Technology Convertible Notes With $130.3M In Principal;  Added Stake In Liberty Broadband Corp With 1,119,893 Shares; Added Stake In AstraZeneca With 2,652,771 Shares

SPAI

Safe Pro Group Q3 Revenue $330.756K Up From $163.547K YoY

The market has been high on Alaunos Therapeutics Inc (TCRT)  stock recently. TCRT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Alaunos Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TCRT!See Full TCRT ReportWhat is Stock Senti

Is Alaunos Therapeutics Inc (TCRT) a Stock to Watch After Losing -8.86% This Week?

Alaunos Therapeutics (TCRT) has released an update. Alaunos Therapeutics, Inc. has successfully regained compliance with Nasdaq's minimum $1.00 bid...

Alaunos Therapeutics Regains Nasdaq Listing Compliance

Alaunos Therapeutics (TCRT) has released an update. Michael Wong resigned as Vice President, Finance of Alaunos Therapeutics, and Ferdinand Groenew...

Alaunos Therapeutics Announces Executive Financial Leadership Changes

Wall Street is positive on Alaunos Therapeutics Inc (TCRT). On average, analysts give Alaunos Therapeutics Inc a Hold rating. The average price target is $2.998, which means analysts expect the stock to climb by 74.30% over the next twelve months.That average ranking earns Alaunos Therapeutics Inc an Analyst Rating of 5, w

How Does Alaunos Therapeutics Inc (TCRT) Stock Rank on Wall Street Friday?

Overall market sentiment has been high on Alaunos Therapeutics Inc (TCRT)  stock lately. TCRT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Alaunos Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TCRT!See Full TCRT ReportWh

Do Traders Think Alaunos Therapeutics Inc (TCRT) Can Keep Climbing Tuesday?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Alaunos Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/"><strong>TCRT</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Alaunos Therapeutics reported earnings per share of -55 cents. This was below the analyst estimate for EPS of -45 cents.</li><li>The company reported revenue of $1,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/tcrt-stock-earnings-alaunos-therapeutics-for-q4-of-2023/">TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Alaunos Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/"><strong>TCRT</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Alaunos Therapeutics reported earnings per share of -11 cents.</li><li>The company reported revenue of $1,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/tcrt-stock-earnings-alaunos-therapeutics-for-q1-of-2024/">TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Alaunos Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/"><strong>TCRT</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Alaunos Therapeutics reported earnings per share of -71 cents.</li><li>The company reported revenue of $4,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/tcrt-stock-earnings-alaunos-therapeutics-for-q2-of-2024/">TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024

The latest announcement is out from Alaunos Therapeutics ( ($TCRT) ). Alaunos Therapeutics, Inc. has decided to terminate its amended licensing agr...

Comments

Alaunos Therapeutics

Alaunos Therapeutics (TCRT) Opciones

Alaunos Therapeutics (NASDAQ:TCRT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL